Fig. 11 | Scientific Reports

Fig. 11

From: Integrating immune multi-omics and machine learning to improve prognosis, immune landscape, and sensitivity to first- and second-line treatments for head and neck squamous cell carcinoma

Fig. 11

Evaluation of immunotherapy response. (A) The RMS time difference by 12 and 24 months after treatment. (B) The LTS difference after 6 months of treatment. (C) A significantly lower CMPIS score in the responder group compared to the nonresponder group. (D-F) Lower CMPIS scores correlated with improved prognostic outcomes post-immunotherapy in the GSE78220 cohort and GSE135222 cohort, as well as better immunotherapy responses in the GSE91061 cohort. (G) Significant differences in priming and activation, trafficking of immune cells to tumors, and infiltration of immune cells into tumors among patients with low CMPIS scores. (H) Higher responsiveness in the low CMPIS group. (I-K) The low CMPIS group exhibited higher MSI scores and Dysfunction scores, while the high CMPIS group displayed elevated Exclusion scores.

Back to article page